Aslan Pharmaceuticals (ASLN) is a clinical-stage immunology company announced positive interim unblinded data from three dose cohorts of its ongoing randomized, double-blind placebo-controlled multiple ascending dose study of ASLAN-004 for moderate to severe atopic dermatitis.
ASLAN004 was well tolerated across all doses. It demonstrated improvements compared . . .
This content is for paid subscribers.
Today’s Highlights March 1, 2021